ADMA Biologics, Inc. (ADMA) P/E Ratio History
Historical price-to-earnings valuation from 2024 to 2026
Loading P/E history...
ADMA Valuation Context
How does the current P/E compare to historical and market benchmarks?
P/E Ratio Analysis
As of May 8, 2026, ADMA Biologics, Inc. (ADMA) trades at a price-to-earnings ratio of 14.1x, with a stock price of $8.47 and trailing twelve-month earnings per share of $0.69.
The current P/E is 60% below its 5-year average of 34.9x. Over the past five years, ADMA's P/E has ranged from a low of 13.3x to a high of 80.9x, placing the current valuation at the 13th percentile of its historical range.
Compared to the Healthcare sector median P/E of 22.3x, ADMA trades at a 37% discount to its sector peers. The sector includes 241 companies with P/E ratios ranging from 0.0x to 177.5x.
Relative to the broader market, ADMA trades at a notable discount to the S&P 500 median P/E of 25.1x. Investors should consider the company's growth prospects, competitive position, and earnings quality when evaluating whether the current valuation is justified.
For a comprehensive intrinsic value estimate using discounted cash flow analysis, see our ADMA DCF Valuation Calculator →
Note: P/E ratio is just one valuation metric. It does not account for balance sheet strength, cash flow quality, or growth sustainability. Always conduct comprehensive due diligence before making investment decisions.
ADMA P/E vs Peers
P/E ratio compared to closely matched public peers
| Company | Market Cap | P/E Ratio | PEG Ratio | EPS Growth (1Y) |
|---|---|---|---|---|
| $7B | 12.1 | - | +148%Best | |
| $7B | 9.2Lowest | - | +143% | |
| $8B | 25.5 | 1.11 | -25% | |
| $15B | 21.1 | 0.87Best | -39% | |
| $53B | 77.6 | 4.10 | -26% | |
| $1B | 31.3 | - | -46% |
Peers sorted by market capitalization. P/E below peers may indicate undervaluation or lower growth expectations. Consider PEG ratio for growth-adjusted comparison.
ADMA Historical P/E Data (2024–2026)
Quarterly P/E ratios calculated from closing price and TTM EPS
| Quarter | Date | Price | TTM EPS | P/E Ratio | vs Avg |
|---|---|---|---|---|---|
| FY2026 Q1 | $9.01 | $0.68 | 13.3x | -62% | |
| FY2025 Q4 | Wed Dec 31 2025 00:00:00 GM | $18.24 | $0.60 | 30.4x | -13% |
| FY2025 Q3 | $14.66 | $0.86 | 17.0x | -51% | |
| FY2025 Q2 | Mon Jun 30 2025 00:00:00 GM | $18.21 | $0.86 | 21.2x | -39% |
| FY2025 Q1 | Mon Mar 31 2025 00:00:00 GM | $19.84 | $0.85 | 23.3x | -33% |
| FY2024 Q4 | $17.15 | $0.82 | 21.0x | -40% | |
| FY2024 Q3 | Mon Sep 30 2024 00:00:00 GM | $19.99 | $0.28 | 72.1x | +107% |
| FY2024 Q2 | Sun Jun 30 2024 00:00:00 GM | $11.18 | $0.14 | 80.9x | +132% |
Average P/E for displayed period: 34.9x
See ADMA's True Return
Price is only half the story. See total return with reinvested dividends.
Launch CalculatorIs ADMA Undervalued?
DCF intrinsic value, peer multiples, and analyst estimates — see what the stock is really worth.
View ValuationCompare ADMA vs DBVT
Side-by-side business, growth, and profitability comparison vs DBV Technologies S.A..
Start ComparisonADMA — Frequently Asked Questions
Quick answers to the most common questions about buying ADMA stock.
Is ADMA stock overvalued or undervalued?
ADMA trades at 14.1x P/E, below its 5-year average of 34.9x. At the 13th percentile of historical range, the stock is priced at a discount to its own history.
How does ADMA's valuation compare to peers?
ADMA Biologics, Inc. P/E of 14.1x compares to sector median of 22.3x. The discount suggests lower growth expectations or higher risk.
What is ADMA's PEG ratio?
ADMA PEG ratio is N/A. Above 2.0 indicates premium valuation relative to growth rate. Historical P/E data spans 2024-2026.